Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough
LAVAL, Québec--(BUSINESS WIRE)--#AIInDrugDevelopment--Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical repo…
LAVAL, Québec--(BUSINESS WIRE)--Altasciences, a fully integrated early-stage drug development organization, and Evidence Matters, a pioneer in data science for clinical trials, are pleased to announce the successful proof-of-concept (POC) of RegulatoryFlow ("RegFlow"). This follows the announcement of the strategic partnership between both companies in August 2025. The POC demonstrated that the efficiency improvements realized by AI
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
